文献速递神经肿瘤

MerTK作为胶质母细胞瘤的治疗靶点

MerTK as a therapeutic target in glioblastoma.
PubMed 文献 · Neuro Oncol · 2018-01-01

研究在配对胶质母细胞瘤(GBM)样本中检测MerTK在肿瘤细胞和巨噬细胞的表达,并在小鼠GBM模型中评估口服MerTK抑制剂UNC2025联合放疗的疗效。结果显示复发肿瘤中MerTK/CD68+巨噬细胞增多,XRT/UNC2025组出现显著生长延迟、19%完全缓解,中位生存与单用XRT相当。作者认为MerTK抑制联合XRT对部分GBM有治疗效应,需进一步机制研究。

要点

  • 复发GBM中MerTK/CD68+巨噬细胞增多,而MerTK/GFAP+肿瘤细胞未见增多。
  • 小鼠模型中XRT/UNC2025组19%完全缓解,存活60天且肿瘤负荷降至治疗前1%-10%。
  • XRT/UNC2025与单用XRT中位生存分别为35天与35天,加用UNC2025未延长中位生存。

核心结论

  • MerTK抑制联合XRT对部分GBM有治疗效应,需进一步机制研究。

研究设计与样本

  • 配对患者GBM样本行双标记免疫组化检测MerTK在肿瘤细胞和巨噬细胞的表达。
  • 在体外和体内研究UNC2025诱导的MerTK抑制。
  • 同系原位同种移植小鼠GBM模型随机接受溶媒、每日UNC2025、分次外照射放疗(XRT)或UNC2025/XRT。

主要发现

  • 复发肿瘤中MerTK/CD68+巨噬细胞增多,而MerTK/胶质纤维酸性蛋白阳性肿瘤细胞未见增多。
  • 药代动力学研究显示UNC2025在同系原位同种移植小鼠GBM模型中肿瘤暴露量高。
  • 溶媒、每日UNC2025、XRT、UNC2025/XRT组中位生存分别为21、22、35、35天,加用UNC2025与否相当。
  • 生物发光成像显示XRT/UNC2025组肿瘤生长显著延迟,19%完全缓解。
  • 缓解小鼠存活60天,肿瘤负荷消退至治疗前生物发光成像的1%-10%,6只中5只组织学无肿瘤。

局限性

  • 作者指出需进一步机制研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioma-associated macrophages and microglia (GAMs) are components of the glioblastoma (GBM) microenvironment that express MerTK, a receptor tyrosine kinase that triggers efferocytosis and can suppress innate immune responses. The aim of the study was to define MerTK as a therapeutic target using an orally bioavailable inhibitor, UNC2025. METHODS: We examined MerTK expression in tumor cells and macrophages in matched patient GBM samples by double-label immunohistochemistry. UNC2025-induced MerTK inhibition was studied in vitro and in vivo. RESULTS: MerTK/CD68+ macrophages increased in recurrent tumors while MerTK/glial fibrillary acidic protein-positive tumor cells did not. Pharmacokinetic studies showed high tumor exposures of UNC2025 in a syngeneic orthotopic allograft mouse GBM model. The same model mice were randomized to receive vehicle, daily UNC2025, fractionated external beam radiotherapy (XRT), or UNC2025/XRT. Although median survival (21, 22, 35, and 35 days, respectively) was equivalent with or without UNC2025, bioluminescence imaging (BLI) showed significant growth delay with XRT/UNC2025 treatment and complete responses in 19%. The responders remained alive for 60 days and showed regression to 1%-10% of pretreatment BLI tumor burden; 5 of 6 were tumor free by histology. In contrast, only 2% of 98 GBM mice of the same model treated with XRT survived 50 days and none survived 60 days. UNC2025 also reduced CD206+ macrophages in mouse tumor samples. CONCLUSIONS: These results suggest that MerTK inhibition combined with XRT has a therapeutic effect in a subset of GBM. Further mechanistic studies are warranted.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wu J, Frady LN, Bash RE, et al. MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018. PMID: 28605477. doi:10.1093/neuonc/nox111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。